

Walking the Line: Opioid Dose De-escalation

Courtney Kominek, PharmD, BCPS, CPE

1

#### **Disclosures**

- Courtney Kominek, PharmD, BCPS, CPE
- The views and opinions expressed in this presentation are those of the authors and do not necessarily reflect the official policy or position of any agency of the United States government, including the Department of Veterans Affairs, as well as employers, employee affiliates and/or pharmaceutical companies mentioned or specific drugs discussed. It was not prepared as part of official government duties for Dr. Kominek.

Painweek.

2

#### **Learning Objectives**

- Identify reasons to initiate an opioid taper, either to a lower dose or to discontinuation.
- Explain how to plan, present to the patient, and execute an opioid taper.
- Describe situations in which opioids should be discontinued.
- If given a patient case, develop an opioid taper plan and provide rationale for continuing to prescribe opioids at a lower dose or discontinuing opioids alltogether.

Painweek.

	1
Question #1	
Mr. Miller is a 57 yo male with LBP prescribed oxycodone CR 40 mg PO Q12H. The patient is also prescribed diazepam 10 mg PO TID PRN for anxiety. He has been stable on this regimen for over 10 years. After discussing	-
the risks, patient opts to taper off the oxycodone CR. How would you taper the patient off?	
A. Reduce by 5 mg/day q3 days	
B. Reduce by 5 mg/day q4 weeks C. Reduce by 10 mg/day q3 days	
D. Reduce by 10 mg/day q4 weeks	
<b>Pain</b> week	
	J
4	
	_
Question #2	
A rapid taper would be indicated in which circumstance	
A. Patient on opioids for 10 years and requesting a taper	
B. Patient with recent overdose     C. Patient with no functional benefit with high dose opioids	-
D. Patient with negative UDM for prescribed scheduled long-acting opioid	
Painweek.	
5	
	1
Current Situation	
<ul> <li>Numerous risks associated with opioids</li> <li>Guidelines and legislation focused on opioid dose</li> </ul>	
Little guidance on when and how to taper  Little guidance on when and how to taper	
<b>POLIN</b> MOOK	

<ul> <li>Recommendation</li> <li>Geared for primar</li> <li>Unintended conse</li> <li>Dismissal from ca</li> </ul>	y care yquences are	
<ul> <li>Challenges with ir or insurance cove</li> </ul>	ing prescribing opioids even when appropriate mplementing nonpharm and nonopioid due to lack of reimbursement rage	
<ul> <li>Misapplication         <ul> <li>Hard limits on ME</li> <li>Abrupt tapering o</li> <li>Groups outside the</li> </ul> </li> </ul>	f opioids	_
Sickle cell     Cancer     Surgery		
NWEEK.	NEJM. 2019;380:2285-2287.	

■ History of drug overdose ■ < 30 years of age

disorder)

Mental disorders (current or history of substance use disorder, depression, generalized anxiety, borderline, antisocial, posttraumatic stress

**Opioid Risks** 

■ Duration of opioids ■ Dose of opioids

 Severe respiratory instability Sleep disordered breathing · Acute psychiatric instability or intermediate-to-high acute suicide risk

PainWeek. VA/DoD Clinical Practice Guidelines for Opioid Therapy for Chronic Pain. February 2017

8

#### **Opioid Risks**

- Co-administration of medication capable of fatal drug-drug interaction
- ■QTc interval > 450 msec with methadone
- Evidence for or history of diversion of (fibromyalgia, headache) controlled substances
- Intolerance, serious adverse effects, or history of inadequate beneficial response to opioids
- Impaired bowel motility unresponsive to therapy
- Traumatic brain injury
- Pain conditions worsened by opioids
- True allergy to opioid agents that can't be resolved by switching classes

·)-	NWEEK.

VA/DoD Clinical Practice Guidelines for Opioid Therapy for Chronic Pain. February 2017.

Reasons to Tap	per		
Improvement in pain	Patient request	Lack of benefit	Adverse effects
High dosage without evidence of benefit from the higher dose	Nonadherence to the treatment plan or unsafe behaviors	Substance use disorder	Opioid overdose
Comorbidities that increase risk	Concomitant medications that increase risk	Mental health comorbidities that can be worsened	Long term treatment with opioid and unclear R vs B
PaiNMACK Dowell D, Haeger Department of ver	ich TM, Chou R; CDC guideline for pre- terans affairs. Veterans Health Administ	auction or Discontinuation of Long-Term of scribing opioids for chronic pain – United ration. PBM Academic Detailing Service. scuments/Pain Opioid Taper Tool IB 1	States, 2016. MMWR 2016;65(1-49). Opioid Taper Decision Tool. October 2016. Available

# **Risks of Rapid Opioid Taper**

- Acute withdrawal symptoms
- Exacerbation of pain
- Psychological distress including thoughts of suicide
- Seek alternate source of opioids

PainWeek HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics, 2019.

11

#### **Potential Taper Benefits** Article Harden et al 2015 Cunningham 2016 et al Frank et al 2016 Sullivan et al 2017 50 patients prescribed chronic opioid therapy and agreed to taper 55 patient taking daily opioid entering IDT pain rehab program 35 patients on chronic opioids and interested in taper Population 24 adult primary care patients Retrospective and prospective chart review Intervention Retrospective review In-person, semi-structured interviews 22-week taper support Baseline and 12 months Usual care Taper support improved significantly more in pain interference, self-efficacy, and opioid problems Outcome Harden P et al. Clinical implications of topology chronic opicids in a veleran population. Plan Med. 2015;16(10):1977-1981... Curring/law X. et al. Opicid beginning in florencyplating selection. Period and interdediction program inhabitation program. Pair med. 2016 Cultimor MO et al. Persophicin opicidate year region for conjustion with ordering pain and another correlation. J John 2017;16(3):203-218. Districts MO et al. Persophicin opicidate yearpoint for conjustion with ordering pain and anotherine correlation. J John 2017;16(3):203-218. Painweek.

Befo			

- Avoid mandating on tapering or discontinuation when justified
   CDC guidelines do not recommend discontinuation when benefits outweigh risks
- Cautionary dosage threshold ≠ mandatory tapering -Follow state licensure requirements
- If patient on opioid and benzodiazepine, coordinate with other provider
- Assist with continued, coordinated care

PainWeek. HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics, 2019.

13

# **Before Initiating Taper**

- Work to optimize nonpharm and nonopioid options for pain
- Assess and treat comorbid mental health conditions
- Asses for suicide risk
- Assess for opioid use disorder if showing signs of opioid misuse
- Discuss with patients increased risk for overdose with returning to previous higher dose
- Provide opioid overdose education and offer naloxone


PainWeck HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics, 2019.


14


# **Partner with Your Patient**


- Discuss risks, benefits, adverse effects, patient concerns
- ■No imminent risk → No need to taper immediately
- Work to get patient buy-in
- Include the patient in the taper decision-making

HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opioid Analgesics, 2019.









# **Opioid Tapering Clinical Pearls**

- Short-term use (<30 days) and low MEDD (<20-30mg) requires no taper
- Do not reverse the opioid taper but pause or slow taper
- For fentanyl patch, reduce the dose by ER/LA opioid and IR opioid 12mcg/hr increments
- Frequent follow-up
- UDM should be performed
- Consider tablet counts or ordering taper in short days supply
- Consider ordering naloxone rescue kit
- Avoid simultaneous tapering of both
- Avoid simultaneous tapering of both opioid and benzodiazepine medications
  - -AMDG guidelines recommend tapering the opioid first

Dowel D. Negerich TM. Chou R. CDC Guideline for Prescribing Opicids for Chronic Plann-United Sales, 2016. MMKR Recomm Rep. 2016;55(b)c. RRV
WORD Clinical Practice Guideline. Narragement of Opicid Therapy for Chronic Plan Webrington, D. C. U.S. Department of Visionens Affairs, version 3.0—2017. Available of https://www.bartagrand.publicalor/Plannicalor.org/ updatefor or promoting opicids for pain. Co. U.S. Department of Visionens Affairs, version 3.0—2017. Available of https://www.bartagrand.publicalor.org/ updatefor or promoting opicids for pain. Co., Opings, WK. Webrington Sales
Pain No. Vision (J. Rethins El J. Teagle by Joseph semp good the page in Arrosi or Economics and recommendation for energial grandom.

Pain C. Vision (J. Rethins El J. Teagle Visione) and promoting or Economics and recommendation for energial grandom.

20

# **Treatment of Opioid Withdrawal Symptoms**

- Gradual reductions typically minimize withdrawal symptoms
- May need to pause or slow taper
- Onset varies on duration of action of opioid
- -Early symptoms: anxiety, restlessness, sweating, yawning, muscle aches, diarrhea, cramping resolve 5-10 days typically
- -Other symptoms: dysphoria, irritability, pain may resolve in weeks to months
- Short-term oral medications available
- -Symptomatic treatment
- -Alpha-2 agonists for autonomic symptoms
- -Others

HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-Term Opiold Analgesics, 2019.

# Side Note: Benzodiazepine Tapering

- ullet Multiple guidelines recommend  $\underline{against}$  the use of concomitant opioids and
- Serious adverse consequences associated with benzodiazepines:
- -Depressed mood
- -Disinhibition
- -Cognitive impairment
- -Falls/hip fractures
- -Traffic accidents
- -Tolerance/dependence
- -Accidental overdose
- -Increased dementia risk?

Painweek.

22

# Side Note: Benzodiazepine Tapering

- May consider switch to a longer acting benzodiazepine
- Reduce dose by 50% the first 2-4 weeks → maintain on that dose for 1-2 months → reduce dose by 25% every 2 weeks
- Slower taper → reduce by 10-25% every 4 weeks

Benzodiazepine	Approximate Dosage Equivalents	Elimination Half-Life
Chlordiazepoxide	25mg	>100 hrs
Diazepam	10mg	>100 hrs
Clonazepam	Img	20-50 hrs
Lorazepam	2mg	10-20 hrs
Alprazolam	Img	12-15 hrs
Temazepam	30mg	10-20 hrs

Painweek.

23

# Side Note: Benzodiazepine Tapering Supratherapeutic Doses Therapeutic Doses -Bedtime Therapeutic Doses - Daytime Consider conversion to long t1/2 drug First dose reduction by 25-30% Subsequently reduce by 5-10% daily to weekly Reduce by ~25% weekly Address potential for rebound insomnia Teach sleep hygiene and provide reassurance Initiate alternate treatment Address potential for rebound anxiety anxiety Last step of withdrawal is likely to be challenging Dosing schedule changes can be challenging (TID → BID) Plan additional psychological support during taper Painweek.

PTSD	Anxiety	Insomnia
• SSRI	• SSRI	Doxepin
• SNRI	• SNRI	Sedative-hypnotics
Mirtazapine		Benzodiazepines
Carbamazepine		Ramelteon
For patient with		Sedating
concomitant pain,		antidepressants
consider duloxetine		Hydroxyzine
or amitriptyline		Melatonin



# 

-	rra	 	_	 

- Mr. Fox is a 55 yo male who recently transferred his care from out-of-state.
  He has been diagnosed with chronic neck and back pain as well as diabetic neuropathy pain.
- His pain medication regimen includes
   Morphine SR 60mg 08H,
   Hydromorphone 4mg PO TID
   Pregabalin 150mg PO BID

  - -Topical lidocaine.
- In reviewing his records brought to the office, nothing significant is noted other than his high dose opioid regimen.
  A random UDM is collected

Painweek.

28

#### Aberrant UDM v1

Immunoassay Test	Result
Opiates	POSITIVE
Oxycodone	NEGATIVE
Methadone	NEGATIVE
Amphetamines	NEGATIVE
Benzodiazepines	NEGATIVE
Cocaine	POSITIVE
Marijuana	NEGATIVE

<b>Confirmatory UDM Results</b>	
Morphine	
Hydromorphone	
Benzoylecgonine	
Pregabalin	

How would you proceed with the opioid taper?

Painweek.

29

# Aberrant UDM v1 - ANSWERED

Characteristic	Recommendations
Type of taper	Do not take over opioid prescribing
Taper regimen	NA
Other recommendations	Offer referral to mental health for treatment of substance use disorder     If X-waivered, offer opioid withdrawal with
	buprenorphine/naloxone Provide naloxone kit and overdose education Offer non-opioid and nonpharmacologic alternatives

Characteristic	Recommendations
Type of taper	Rapid
Taper regimen	Taper morphine SR first
	45mg PO Q8H x7 days 30mg PO Q8H x7 days
	30mg PO Q12H x7 days 15mg PO Q12H x7 days STOP
	Then, taper hydromorphone 2mg PO TID 7 days
	2mg PO BID 7 days 2mg PO daily 7 days STOP
Other recommendations	Offer referral to mental health for treatment of substance use disorder
	Provide naloxone kit and overdose education
	Offer non-opioid and nonpharmacologic alternative

#### Aberrant UDM v2

- Ms. Smith is a 45 yo female diagnosed with a combination of chronic low back pain and HIV neuropathy pain.
- She is currently prescribed methadone 10mg PO Q8H in addition to gabapentin and duloxetine.
- She follows regularly with the pain psychologist and is active in a local yoga group.
- While she has a remote history of alcohol misuse and marijuana use, her UDM have been appropriate for the last several years. As part of routine opioid compliance monitoring, a random UDM is collected.

Painweek.

32

# Aberrant UDM v2

Immunoassay Test	Result
Opiates	NEGATIVE
Oxycodone	NEGATIVE
Methadone	POSITIVE
Amphetamines	NEGATIVE
Benzodiazepines	NEGATIVE
Cocaine	NEGATIVE
Marijuana	POSITIVE

Comprehensive UDM Results
Methadone
EDDP
THC
Gabapentin

How would you proceed with the opioid taper?

**Painweek** 

Characteristic	Recommendations
ype of taper	Slower
Taper regimen	Taper methadone I Omg-Smg-I Omg (separate doses by 8 hours) x4 weeks I Omg PO BID x4 weeks Smg PO QAM + I Omg PO QHS x4 weeks, Smg PO BID x4 weeks Smg PO daily x4 weeks STOP
Other recommendations	Offer referral to mental health for treatment of substance use disorder     Provide naloxone kit and overdose education     Offer non-opioid and nonpharmacologic pain managemen

#### Aberrant UDM v2 ANSWERED



- Alternate plan:
- -One-time warning and continuation of opioid therapy as currently prescribed
- -Counsel/educate patient on the plan to taper opioids should she test positive for marijuana again
- -Repeat UDM at more regular intervals at future appointments

Painweek.

35

# Aberrant UDM v3

- Mr. White is a 63 yo man followed in the chronic pain clinic for chronic cervical pain with radiculopathy as well as diabetic neuropathy pain.
- •He presents to his regular follow-up appointment for medication renewal in his motorized scooter, but is sedated in clinic, even falling asleep during the clinical interview.
- ■He is prescribed morphine SR 30mg PO Q12H and morphine IR 7.5mg PO BID PRN pain.
- He admits to occasionally taking his wife's sleep medication at night, but otherwise denies medication misuse.
- A random UDM is collected.

Painweek.

#### Aberrant UDM v3

Immunoassay Test	Result	
Opiates	POSITIVE	
Oxycodone	NEGATIVE	
Methadone	NEGATIVE	
Amphetamines	NEGATIVE	
Benzodiazepines	POSITIVE	
Cocaine	NEGATIVE	
Marijuana	NEGATIVE	

Comprehensive UDM Results	
Morphine	
-lydromorphone	
Vordiazepam	
Temazepam	
Oxazepam	

How would you proceed with the opioid taper?

Painweek.

37

# Aberrant UDM v3 ANSWERED Characteristic Recommendations Type of taper Faster Taper regimen Taper morphine SR first Ising PO QNH x7 days Ising PO QNH x3 days Ising PO QNH x3 days STOP Then, taper morphine IR Decrease to 7.5mg PO daily PRN x7 days STOP Other recommendations - Provide naloxone kit Offer non-opioid and nonpharmacologic pain management.

38

# Aberrant UDM v4

- Ms. Coon is a 39 yo female patient diagnosed with chronic knee pain.
- She is a relatively new patient to your clinic, but has not demonstrated any aberrant behaviors.
- She has trialed acupuncture and tai chi and completed an 8-week chronic pain group.
- Currently, she is prescribed fentanyl patch 25 mcg/hr apply Q72H as well as milnacipran and amitriptyline for her pain.
- During the clinic visit, you visualize the patch in place on her left upper arm and confirm the patch strength. She confirms changing the patch as instructed and denies having any issues with the patch falling off.
- A random UDM is collected as part of opioid compliance monitoring.

Painweek.

# Aberrant UDM v4

Immunoassay Test	Result
Opiates	NEGATIVE
Oxycodone	NEGATIVE
Methadone	NEGATIVE
Amphetamines	NEGATIVE
Benzodiazepines	NEGATIVE
Cocaine	NEGATIVE
Marijuana	NEGATIVE
Fentanyl	NEGATIVE

Prior to sending for comprehensive UDM you discuss the results with the patient.

Painweek.

40

#### **Aberrant UDM v4 ANSWERED**



Characteristic	Recommendations
Type of taper	None needed
Taper regimen	Not using fentanyl patch regularly or appropriately (and admits to just putting the patch on in the morning of her scheduled appointments), no taper is warranted
Other recommendations	Depending on the circumstance, offer referral to mental health for SUD treatment     Offer non-opioid pain management

Painweek.

41

# No Functional Benefit

- Mr. Hunter is a 72 yo man who has been on chronic opioid therapy for 10+ years.
- He has been referred to the chronic pain clinic by his PCP as he is no longer active and is now using a motorized scooter to get around. He no longer does household chores or yard work and refuses to try a walking regimen using an assistive device.
- He admits to feeling depressed but also reports 10/10 pain on his current opioid regimen of oxycodone CR 40mg PO Q12H and oxycodone/acetaminophen 10/325mg 1 tab PO QID PRN pain.
- He agrees to work with the pain psychologist and trial acupuncture. You have also convinced him to start duloxetine for both depression and chronic pain.
- How would you proceed with the opioid taper?

Painweek.

<sup>■</sup> How would you proceed with the opioid taper?

Characteristic Recommendations		
Type of taper	Slower	
Taper regimen	Taper oxycodone CR first 30mg PO QAM + 40mg PO QHS x4 weeks 30mg PO Q12H x4 weeks 20mg PO QAM + 30mg PO QHS x4 weeks 20mg PO Q12H x4 weeks 10mg PO QAM + 20mg PO QPM x4 weeks 10mg PO Q12H x4 weeks 10mg PO Q12H x4 weeks 5TOP	Then, taper oxycodone/acetaminophen 10/325mg i tab PO TID PRIN 44 weeks 10/325mg i tab PO BID PRN 54 weeks 5/325mg i tab PO BID PRN 54 weeks 5/325mg i tab PO daily PRN x4 weeks STOP
Other recommendations	Provide naloxone kit and overdose education     Offer non-opioid and nonpharmacologic pain m	

# No Functional Benefit ANSWERED (Alternative) Characteristic Recommendations Type of taper Slower Convert then taper regimen Provide increments Other Provide naloxone kit and overdose education Procommendations Other Other Other Other Other Other Provide naloxone kit and overdose education Other Other

44

# **Trial Reduction to Lower Dose**

- •Ms. Fields is a 40 yo female and a former patient of the chronic pain clinic, now re-consulted by her PCP for opioid dose reduction to be in compliance with the 2016 CDC guideline recommendations.
- Her current pain medication regimen includes fentanyl patch 100 mcg/hr apply Q48H, oxycodone IR 30mg PO QID PRN, and gabapentin 1200mg PO TID.
- She is reluctant to proceed with the opioid taper and admits to being scared because she does not know how she will function on a lower dose of opioids.
- She refuses to engage in other pain clinic services at this time, but agrees to reconsider them in the future depending on how she feels as the opioids are being tapered.
- How would you proceed with the opioid taper?

Painweek.

Characteristic	Recommendations	
Type of taper	Slower	Disclaimer:
Taper regimen	Taper fentanyl patch first – goal 25 mcg/hr Q72H (60 MEDD)  Reduce by 12 mcg/hr q4 weeks Then, taper oxycodone IR – goal 20 mg/day (30 MEDD) Decrease by 10 mg/day q4 weeks until at 20 mg PO q6h Then reduce by 5 mg/day q4 weeks	Consider the risks:benefits of continuing opioid therapy. Don't just taper to tape and don't just treat the MEDD
Other recommendations	May need to pause opioid taper     Provide naloxone kit and overdose education     Offer non-opioid and nonpharmacologic pain management	number – treat the WHOLE patient.

#### **Concomitant Benzodiazepine**

- Mr. Pitt is a 33 yo man diagnosed with chronic low back pain as well as anxiety and PTSD.
- •He has been managing his chronic pain with morphine IR 30mg PO QID PRN, but has refused other pain management modalities.
- For his anxiety he is prescribed sertraline as well as alprazolam 1mg PO TID PRN.
- You have discussed the increased risks for respiratory depression and overdose associated with the combination of opioids and benzodiazepines.
- Pt prefers to continue his benzodiazepine and taper his opioid while pursuing non-opioid pain management strategies.
- How would you proceed with the opioid taper?

Painweek.

47

Characteristic	Recommendations
Type of taper	Slower
Taper regimen	Taper morphine IR 15mg PO QAM + 30mg PO TID x4 week: 15mg-30mg-30mg-15mg x4 weeks
	15mg-15mg-30mg-15mg x4 weeks 15mg PO q6h x4 weeks 15mg PO TID x4 weeks
	I5mg PO BID x4 weeks, 7.5mg PO BID x4 weeks,
	7.5mg PO daily x4 weeks STOP
Other recommendations	Provide naloxone kit
	May need to pause opioid taper     Offer non-opioid and nonpharmacologic
	pain management

#### **Significant Comorbidities**

- Ms. Carter is a 62 yo female with post laminectomy syndrome.She has COPD with moderate control.
- Recently, her husband reported that she snores a lot at night, so she had a sleep study completed. The report states that she has severe sleep apnea. She just went to get her CPAP and she refuses to take it home with her.
- She is currently prescribed hydrocodone ER 40 mg PO q12h.
- How would you proceed with the opioid taper?

Painweek.

49

Characteristic	Recommendations
Type of taper	Slower
aper regimen	Taper hydrocodone ER
	30 mg PO QAM and 40 mg PO QHS x2-4 weeks
	30 mg PO q12h x2-4 weeks
	20 mg PO QAM and 30 mg PO QHS x 2-4 weeks
	20 mg PO q12h x2-4 weeks
	15 mg PO QAM and 20 mg PO QHS x2-4 weeks
	15 mg PO q12h x2-4 weeks
	10 mg PO QAM and 15 mg QHS x2-4 weeks
	10 mg PO q12h x2-4 weeks
	10 mg PO daily x2-4 weeks
	STOP
Other	Provide naloxone kit and overdose education
recommendations	May need to pause opioid taper
	Offer non-opioid and nonpharmacologic pain management

# 50

#### Significant PDMP Query Results

- ■Mr. Oz is a 79 yo male who has been a patient of his local retail pharmacy for
- As the float pharmacist covering for the weekend, you review the prescriptions he drops off to have filled: oxycodone CR 80mg PO Q8H and oxycodone IR 30mg PO TID PRN pain.
- You feel that it would be most appropriate to check the state's PDMP database prior to filling the prescription, as there are no notes on his file indicating that this has been done recently.
- Your query includes the last calendar year and the results are quite startling; he has been filling oxycodone CR and IR prescriptions via self-pay at another retail pharmacy about 30 minutes away every month for the last 8 months.


How would you proceed with the opioid taper?

Characteristic	Recommendations	
Type of taper	No taper needed	Rapid
Taper regimen	Filling duplicate opioids at another pharmacy for several months, no taper is warranted	Taper long-acting first reducing dose every 3-5 day until at lowest dosage form then reduce dosing frequency. Then taper short-acting by reducing dose every 3-5 days then reduce dosing frequency.
Other recommendations	Alert both prescribing providers to the significant	
recommendations	Offer opioid overdose e	ducation and at-home
	naloxone	
Į.	Offer and arrange OUD	treatment

#### **Recent Overdose**

- Mr. Ocean is a 52 yo man diagnosed with CRPS in the RLE due to an injury
- He had been stable on his regimen of hydrocodone/acetaminophen 10/325mg PO q6h PRN in combination with clonidine and venlafaxine SA
- However his wife has contacted the clinic to alert you that he has been admitted to a local hospital due to opioid overdose.
- The patient presents to the clinic 2 days post-hospital discharge.
- He indicates that he has been taking more hydrocodone/acetaminophen than prescribed (up to 8-10 tablets per day) and had been drinking alcohol due to his pain and feeling depressed the day he overdosed.
- The hospital discharged him on a lower dose of hydrocodone/acetaminophen (5/325mg) and patient reports having 10 tablets left.
- How would you proceed with the opioid taper?

53



# Benzodiazepine Taper

- Ms. Bloomfield is a 45 yo female diagnosed with low back pain and cervicalgia as well as anxiety.
- She is taking morphine SR 30mg Q12H, oxycodone IR 5mg PO QID PRN pain, duloxetine 60mg PO daily, and diazepam 5mg PO TID PRN anxiety.
- As her primary care provider, you review the most recent guideline recommendations regarding concomitant benzodiazepine and opioid use as well as your concerns for her safety.
- During this open conversation, she expresses her wish to taper off diazepam and remain on her opioids for ongoing pain management.

Painweek.

55

haracteristics	Recommendations
pe of taper	Benzodiazepine
per regimen	Taper diazepam 5mg:  7.5mg (1.5 tabs) PO BID x1-2 months 5mg (1 tab) PO QAM + 7.5mg (1.5 tabs) PO QPM x2 weeks 5mg (1 tab) tab PO BID x2 weeks 2.5mg (½ tab) PO QAM + 5mg (1 tab) PO QPM x2 weeks 2.5mg (½ tab) PO BID x2 week 2.5mg (½ tab) PO BiD x2 week 5.5mg (½ tab) PO daily x2 weeks 5.5mg (½ tab) PO daily x2 weeks
ther recommendations	Provide naloxone kit and overdose education     Offer non-benzodiazepine and nonpharmacologic anxiety treatment/interventions

56

#### 3 Things for Monday

- All about risks vs. benefits
- ■Speed of taper is determined by reason for taper
- Utilize risk mitigation strategies during tapers

Painweek.

	_					
1	О.	ıΔ	et	ın	n	#1

- Mr. Miller is a 57 yo male with LBP prescribed oxycodone CR 40 mg PO Q12H. The patient is also prescribed diazepam 10 mg PO TID PRN for anxiety. He has been stable on this regimen for over 10 years. After discussing the risks, patient opts to taper off the oxycodone CR. How would you taper the patient off?
- A. Reduce by 5 mg/day q3 days
- B. Reduce by 5 mg/day q4 weeks
- C. Reduce by 10 mg/day q3 days
- D. Reduce by 10 mg/day q4 weeks

Painweek.

58

#### Question #2

- A rapid taper would be indicated in which circumstance
- A. Patient on opioids for 10 years and requesting a taper
- B. Patient with recent overdose
- C. Patient with no functional benefit with high dose opioids
- D. Patient with negative UDM for prescribed scheduled long-acting opioid

Painweek.

59



Walking the Line: Opioid Dose De-escalation

Courtney Kominek, PharmD, BCPS, CPE & Abigail Brooks, PharmD, BCPS